Bluejay Diagnostics Approves 1-for-4 Reverse Stock Split
3 reports, 1 independent
Updated Oct 30
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bluejay Diagnostics, Inc. approved a reverse stock split at a ratio of 1-for-4. The split will become effective on November 3, 2026, combining every four issued shares into one. This action is expected to reduce the company's outstanding common stock from approximately 4,468,051 shares to approximately 1,117,013 shares.
From finanznachrichten.de
Why it matters
The reverse stock split is a corporate action that changes the company's share structure and trading mechanics. Bluejay Diagnostics is a medical diagnostics company that utilizes Symphony's near-patient diagnostic platform.
From finanznachrichten.de
Who's involved
- SymphonyProvides the near-patient diagnostic platform used by Bluejay Diagnostics
- MarketBeatTracks financial information related to corporate actions
Keep exploring
The entities involved
-
Symphony
fintech company
Nothing else this week.